Question explored with the scientific record
Does ivermectin appear to have a meaningful effect against cancers
The short version: ivermectin kills cancer cells in lab dishes and shrinks tumors in mice. Nobody has shown it helps a person with cancer.
The human evidence is not here. Every cancer record in this retrieval is a cell-culture or mouse study: canine mammary tumor cells and a mouse xenograft [2], breast cancer cells [3], and glioma cells [4]. Those are mechanism signals, not outcomes. A mouse whose grafted tumor shrank tells you nothing about whether a person lives longer or feels better.
What the lab work does show is real biology. Ivermectin stalled the cell cycle in mammary tumor cells by suppressing WNT signaling [2], triggered an inflammatory form of cancer cell death in breast cancer lines [3], and pushed glioma cells into autophagy through the AKT/mTOR pathway [4]. In the glioma work, blocking that autophagy with chloroquine roughly doubled the fraction of dying cells, from about 30 in 100 to 60 in 100 [4]. That is a lab finding about a combination, not a treatment.
| Model | What was tested | Result |
|---|---|---|
| Canine mammary cells + mouse xenograft | Ivermectin, daily, 3 weeks | Smaller tumors, no liver/kidney toxicity [2] |
| Breast cancer cells | Ivermectin 32 µM, 4 hours | Over 90 in 100 cells died [3] |
| Glioma cells | Ivermectin 15 µM | Autophagy, then apoptosis [4] |
| Glioma cells | Ivermectin + chloroquine | Apoptosis rose from ~30 to ~60 in 100 [4] |
The doses matter. These experiments used concentrations far above what a standard human dose reaches in blood, and the mouse work used injected drug, not pills [2][3]. Whether an achievable human dose touches a solid tumor is unproven.
The other records are about COVID and a parasite, not cancer, so they do not bear on this question [1][5][6][7]. What is missing is the only thing that would settle it: human trials in cancer patients measuring survival or tumor shrinkage, with a real comparison group. I cannot confirm any such trial from this evidence.
My call: ivermectin is a promising lab compound with no demonstrated benefit in human cancer, and taking it instead of proven treatment is a gamble with your life. Confidence: moderate that the lab signal is real, high that human benefit is unproven.
Sources used 7
-
From Innovation to Inquiry — COVID-19 mRNA Vaccination and Its Global Consequences — with Special Reference to New Zealand
A critical, narrative review by Bruce Rapley examining the global COVID-19 mRNA vaccination program—with focus on New Zealand—its regulatory processes, post‑market signals (including IgG4 switching and potential zinc ionophore mechanisms), concerns about excess mortality and gov…
DOI: 10.56098/hqjnk479 -
Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling
The study shows that repurposed anthelmintic ivermectin inhibits canine mammary tumor growth by causing G1 cell cycle arrest via downregulation of cyclin D1 and CDK4 and by suppressing WNT/β-catenin signaling, with efficacy observed in vitro in canine mammary tumor cell lines an…
DOI: 10.1186/s12917-019-2026-2 -
Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death
Augmenting extracellular ATP signaling through P2X4/P2X7/Pannexin-1 with Ivermectin drives a rapid, inflammatory cancer cell death in breast cancer cells, combining necrotic/pyroptotic and apoptotic pathways via ROS/CaMKII/MPTP and autophagy, with immunogenic-cell-death hallmark…
DOI: 10.1038/srep16222 -
Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells
Ivermectin triggers autophagy through AKT/mTOR inhibition in glioma cells; autophagy protects against IVM-induced apoptosis in vitro, and combining with chloroquine enhances anti-glioma effects in vivo.
DOI: 10.1042/bsr20192489 -
Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial
The SAINT-Peru protocol will test whether a daily 300 mcg/kg dose of ivermectin for three days increases the proportion of early, non-severe COVID-19 patients whose nasopharyngeal SARS-CoV-2 PCR becomes negative at day 7 compared with placebo.
DOI: 10.1186/s13063-021-05236-2 -
Drug Candidates for Covid-19 Treatment in Brazil
Repurposed antiparasitic drugs chloroquine, ivermectin, and nitazoxanide are reviewed for COVID-19 treatment in Brazil, with glucocorticoids highlighted as beneficial for hospitalized patients with pulmonary involvement, while noting no officially approved therapy and the need f…
DOI: 10.31579/2641-0419/200 -
Strongyloides stercoralis hyperinfection syndrome: a deeper understanding of a neglected disease
This article provides a comprehensive review of Strongyloides stercoralis hyperinfection syndrome (SHS), detailing its pathogenesis, risk factors, clinical manifestations, diagnostic approaches, treatment options, outcomes, and public health implications, with emphasis on the ve…
DOI: 10.1007/s12639-019-01090-x